Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

49.66 -0.45 (-0.91%)
Streaming Delayed Price Updated: 10:49 AM EDT, Aug 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,467,805
Open 49.97
Bid (Size) 49.65 (13)
Ask (Size) 49.66 (11)
Prev. Close 50.11
Today's Range 49.57 - 50.06
52wk Range 40.94 - 61.71
Shares Outstanding 5,606,688,356
Dividend Yield 3.14%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Landmark Drug Pricing Reform Bill Passes Congress House
The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for the first time and capping seniors’ drug expenses to $2,000 per year... 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga

Performance

YTD
-12.35%
-12.35%
1 Month
-4.05%
-4.05%
3 Month
-2.00%
-2.00%
6 Month
-0.29%
-0.29%
1 Year
+1.52%
+1.52%

More News

Read More
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
Via Investor's Business Daily
Blue Water Vaccines: Early Stage Developer Of Infectious Disease Vaccines
Via Talk Markets
Pfizer's 20-Valent Pneumococcal Vaccine Hits Primary Goal In Infant Trial
Via Benzinga
Pfizer Shares Ascend Following Positive Data From Late-Stage Pneumococcal Vaccine Trial For Infants
Via Benzinga
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
From Pfizer Inc.
Via Business Wire
4 Dividend Stocks Set to Move Significantly Higher This Year
Via InvestorPlace
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke
Via Benzinga
GSK, PFE, SNY Stocks Fall on Zantac Litigation
Via InvestorPlace
Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer
Via Benzinga
Pharmaceutical Companies Report Gearing Up To Combat COVID Variants This Fall
Via Benzinga
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Super Bullish Or Bearish On Tesla Or Apple? These New ETFs Are For You
Via Benzinga
7 Blue-Chip Stocks That Will Survive 2022
Via InvestorPlace
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Via MarketBeat
Topics ETFs
Exposures COVID-19
Why Is Novavax (NVAX) Stock Plunging 30%?
Via InvestorPlace
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Via Benzinga
7 Blue-Chip Stocks to Buy Now for Growth and Dividends
Via InvestorPlace
The 3 Best Vanguard Funds to Buy in August
Via InvestorPlace
Recap of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Pfizer And Valneva Commence Late-Stage Lyme Disease Study
Via Benzinga
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
From Pfizer Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.